<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01111396</url>
  </required_header>
  <id_info>
    <org_study_id>EK153052009</org_study_id>
    <nct_id>NCT01111396</nct_id>
  </id_info>
  <brief_title>Longitudinal Investigation of Hippocampal Function and Morphology in Acute Lymphatic Leukemia (ALL) Patients Treated With Chemotherapy</brief_title>
  <acronym>HIF-ALL</acronym>
  <official_title>Longitudinal Investigation of Hippocampal Function and Morphology in ALL Patients Treated With Chemotherapy: A Monocentric, Interdisciplinary Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universit채t Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Martin-Luther-Universit채t Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universit채t Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are two regions in the adult brain that exhibit neuronal stem and progenitor cells,
      generating new neurons postnatally and throughout adulthood. One is the so called
      subventricular zone the other is the dentate gyrus of the hippocampus. Adult neurogenesis is
      a physiological process representing an important functional impact for certain brain areas,
      especially the hippocampus. The hippocampal formation plays an important role in long-term
      memory and spatial navigation. Inhibition of adult neurogenesis in mice by chemotherapy or
      radiation is followed by significant deficits in hippocampal memory functions while
      hippocampus-independent memory is unaffected.

      Clinical trials had shown that chemotherapy and brain radiation lead to cognitive
      dysfunction. However, the exact mechanisms underlying this phenomenon are still unidentified.

      The aim of our study is to investigate, whether the inhibition of adult neural stem cell
      proliferation in the hippocampus by intrathecal chemotherapy and/or cerebral radiation is
      responsible for treatment induced memory deficits. We will investigate patients suffering
      from acute lymphatic leukaemia (ALL) that receive prophylactic intrathecal chemotherapy and
      brain irradiation. The study represents a longitudinal investigation including a virtual
      &quot;humanized&quot; version of the morris-water-maze to test hippocampus dependent spatial memory, as
      well as MR-imaging for morphological (volumetry) and biochemical (spectroscopy) data.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hippocampal function measured with virtual water maze test</measure>
    <time_frame>day 0</time_frame>
    <description>The hippocampal function will by studies in a longitudinal manner and thus we plan to measure the water maze test performance at several time points (time frames) of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hippocampal function measured with virtual water maze test</measure>
    <time_frame>day 9</time_frame>
    <description>The hippocampal function will by studies in a longitudinal manner and thus we plan to measure the water maze test performance at several time points (time frames) of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hippocampal function measured with virtual water maze test</measure>
    <time_frame>day 16</time_frame>
    <description>The hippocampal function will by studies in a longitudinal manner and thus we plan to measure the water maze test performance at several time points (time frames) of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hippocampal function measured with virtual water maze test</measure>
    <time_frame>day 52</time_frame>
    <description>The hippocampal function will by studies in a longitudinal manner and thus we plan to measure the water maze test performance at several time points (time frames) of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hippocampal function measured with virtual water maze test</measure>
    <time_frame>day 70</time_frame>
    <description>The hippocampal function will by studies in a longitudinal manner and thus we plan to measure the water maze test performance at several time points (time frames) of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hippocampal function measured with virtual water maze test</measure>
    <time_frame>week 36</time_frame>
    <description>The hippocampal function will by studies in a longitudinal manner and thus we plan to measure the water maze test performance at several time points (time frames) of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hippocampal morphology measured by MRI</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hippocampal morphology measured by MRI</measure>
    <time_frame>day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hippocampal morphology measured by MRI</measure>
    <time_frame>day 70</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hippocampal morphology measured by MRI</measure>
    <time_frame>week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood cell count</measure>
    <time_frame>day 0</time_frame>
    <description>Since we investigate a subpopulation of the GMALL 2003 chemotherapy study, all safety measures of the GMALL 2003 study are performed in the population of the present study.
Peripheral blood cell counts for estimating the chemotherapy toxicity according to WHO criteria and the minimal residual disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood cell count</measure>
    <time_frame>day 26</time_frame>
    <description>Since we investigate a subpopulation of the GMALL 2003 chemotherapy study, all safety measures of the GMALL 2003 study are performed in the population of the present study.
Peripheral blood cell counts for estimating the chemotherapy toxicity according to WHO criteria and the minimal residual disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood cell count</measure>
    <time_frame>day 46</time_frame>
    <description>Since we investigate a subpopulation of the GMALL 2003 chemotherapy study, all safety measures of the GMALL 2003 study are performed in the population of the present study.
Peripheral blood cell counts for estimating the chemotherapy toxicity according to WHO criteria and the minimal residual disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood cell count</measure>
    <time_frame>day 71</time_frame>
    <description>Since we investigate a subpopulation of the GMALL 2003 chemotherapy study, all safety measures of the GMALL 2003 study are performed in the population of the present study.
Peripheral blood cell counts for estimating the chemotherapy toxicity according to WHO criteria and the minimal residual disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood cell count</measure>
    <time_frame>week 16</time_frame>
    <description>Since we investigate a subpopulation of the GMALL 2003 chemotherapy study, all safety measures of the GMALL 2003 study are performed in the population of the present study.
Peripheral blood cell counts for estimating the chemotherapy toxicity according to WHO criteria and the minimal residual disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood cell count</measure>
    <time_frame>week 22</time_frame>
    <description>Since we investigate a subpopulation of the GMALL 2003 chemotherapy study, all safety measures of the GMALL 2003 study are performed in the population of the present study.
Peripheral blood cell counts for estimating the chemotherapy toxicity according to WHO criteria and the minimal residual disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood cell count</measure>
    <time_frame>week 30</time_frame>
    <description>Since we investigate a subpopulation of the GMALL 2003 chemotherapy study, all safety measures of the GMALL 2003 study are performed in the population of the present study.
Peripheral blood cell counts for estimating the chemotherapy toxicity according to WHO criteria and the minimal residual disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood cell count</measure>
    <time_frame>week 41</time_frame>
    <description>Since we investigate a subpopulation of the GMALL 2003 chemotherapy study, all safety measures of the GMALL 2003 study are performed in the population of the present study.
Peripheral blood cell counts for estimating the chemotherapy toxicity according to WHO criteria and the minimal residual disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood count</measure>
    <time_frame>week 52</time_frame>
    <description>Since we investigate a subpopulation of the GMALL 2003 chemotherapy study, all safety measures of the GMALL 2003 study are performed in the population of the present study.
Peripheral blood cell counts for estimating the chemotherapy toxicity according to WHO criteria and the minimal residual disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone marrow examination</measure>
    <time_frame>day 0</time_frame>
    <description>Since we investigate a subpopulation of the GMALL 2003 chemotherapy study, all safety measures of the GMALL 2003 study are performed in the population of the present study.
Bone marrow examination is investigated to extimate minimal residual disease activity and chemotherapy toxicity according to WHO criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone marrow examination</measure>
    <time_frame>day 26</time_frame>
    <description>Since we investigate a subpopulation of the GMALL 2003 chemotherapy study, all safety measures of the GMALL 2003 study are performed in the population of the present study.
Bone marrow examination is investigated to extimate minimal residual disease activity and chemotherapy toxicity according to WHO criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone marrow examination</measure>
    <time_frame>day 46</time_frame>
    <description>Since we investigate a subpopulation of the GMALL 2003 chemotherapy study, all safety measures of the GMALL 2003 study are performed in the population of the present study.
Bone marrow examination is investigated to extimate minimal residual disease activity and chemotherapy toxicity according to WHO criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone marrow examination</measure>
    <time_frame>day 71</time_frame>
    <description>Since we investigate a subpopulation of the GMALL 2003 chemotherapy study, all safety measures of the GMALL 2003 study are performed in the population of the present study.
Bone marrow examination is investigated to extimate minimal residual disease activity and chemotherapy toxicity according to WHO criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone marrow examination</measure>
    <time_frame>week 16</time_frame>
    <description>Since we investigate a subpopulation of the GMALL 2003 chemotherapy study, all safety measures of the GMALL 2003 study are performed in the population of the present study.
Bone marrow examination is investigated to extimate minimal residual disease activity and chemotherapy toxicity according to WHO criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone marrow examination</measure>
    <time_frame>week 22</time_frame>
    <description>Since we investigate a subpopulation of the GMALL 2003 chemotherapy study, all safety measures of the GMALL 2003 study are performed in the population of the present study.
Bone marrow examination is investigated to extimate minimal residual disease activity and chemotherapy toxicity according to WHO criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone marrow examination</measure>
    <time_frame>week 30</time_frame>
    <description>Since we investigate a subpopulation of the GMALL 2003 chemotherapy study, all safety measures of the GMALL 2003 study are performed in the population of the present study.
Bone marrow examination is investigated to extimate minimal residual disease activity and chemotherapy toxicity according to WHO criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone marrow examination</measure>
    <time_frame>week 41</time_frame>
    <description>Since we investigate a subpopulation of the GMALL 2003 chemotherapy study, all safety measures of the GMALL 2003 study are performed in the population of the present study.
Bone marrow examination is investigated to extimate minimal residual disease activity and chemotherapy toxicity according to WHO criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone marrow examination</measure>
    <time_frame>week 52</time_frame>
    <description>Since we investigate a subpopulation of the GMALL 2003 chemotherapy study, all safety measures of the GMALL 2003 study are performed in the population of the present study.
Bone marrow examination is investigated to extimate minimal residual disease activity and chemotherapy toxicity according to WHO criteria.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Acute Lymphatic Leukemia</condition>
  <arm_group>
    <arm_group_label>Patient with ALL under chemotherapy</arm_group_label>
    <description>This group consists of patients with initial diagnosis of acute lymphatic leukemia (ALL), who are enrolled into the GMALL 2003 chemotherapy study. There is no change of the initial GMALL 2003 treatment protocol for the present study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients of the Department of Internal Medicine at the Dresden University of
        Technology hospital, who are initially diagnosed of acute lymphatic leukemia (ALL) and
        included into the GMALL 2003 chemotherapy study. All treatment procedures and outcome
        measurements of the GMALL 2003 study (most importantly also the safety outcome measures)
        are regularly performed in the sub population of the present sub study. Inclusion and
        exclusion criteria are given below.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Initial diagnosis of acute lymphatic leukaemia (ALL)

          -  Treatment within the German Multicenter Adult ALL (GMALL 2003) therapy study

          -  Age 18 to 40 years

          -  Eligibility for performing study procedure

          -  Informed consent

        Exclusion Criteria:

          -  Neuropsychiatric disorders

          -  Present contraindication for MRI investigation (e.g. pacemaker)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Storch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universit채t Dresden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moritz Brandt, MD</last_name>
    <phone>+49-351-458</phone>
    <phone_ext>18507</phone_ext>
    <email>moritz.brandt@uniklinikum-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kalina Brandt, MD</last_name>
    <phone>+49-351-458</phone>
    <phone_ext>2610</phone_ext>
    <email>kalina.brandt@uniklinikum-dresden.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dresden University of Technology University Hospital</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moritz Brandt, MD</last_name>
      <phone>+49-351-458</phone>
      <phone_ext>18507</phone_ext>
      <email>moritz.brandt@uniklinikum-dresden.de</email>
    </contact>
    <contact_backup>
      <last_name>Kalina Brandt</last_name>
      <phone>+49-351-458</phone>
      <phone_ext>2610</phone_ext>
      <email>kalina.brandt@uniklinikum-dresden.de</email>
    </contact_backup>
    <investigator>
      <last_name>Kalina Brandt</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Moritz Brandt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Bornhaeuser, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Storch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annett Werner, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markus Schaich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <last_update_submitted>April 26, 2010</last_update_submitted>
  <last_update_submitted_qc>April 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Professor Alexander Storch, MD</name_title>
    <organization>Dresden University of Technology</organization>
  </responsible_party>
  <keyword>ALL</keyword>
  <keyword>GMALL 2003</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Hippocampus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

